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Service  d’imagerie  médicale,  hospices  civils  de  Lyon,  hôpital  de  la  Croix-Rousse,  69004  Lyon,
FranceObservation
A  78-year-old  female  patient  with  no  notable  history  was  hospitalised  for  investigation  of
her  altered  general  condition.  An  abdominopelvic  ultrasound  examination  was  performed
to  determine  the  aetiology.  This  showed  a  mixed  7  cm  left  ovarian  mass  comprised  of
a  multilocular  cystic  part  and  a  tissue  part.  There  was  also  ascites.  The  right  ovary  was
atrophic  and  ﬁbrous.  Laboratory  tests  were  performed  and  found  a  CA125  level  of  164  U/mL
(N  <  35  U/mL).  A  pelvic  MRI  was  added  to  the  series  of  examinations  (Figs.  1  and  2).Figure 1. Axial T2 sequence.
DOI of original article:10.1016/j.diii.2012.03.011.
 Here is the answer to the case previously published in the no 05/2012. As a reminder we publish again the entire case with the
response following.
∗ Corresponding author.
E-mail address: noemiepeyron@hotmail.com (N. Peyron).
2211-5684/$ — see front matter © 2012 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.diii.2012.03.012
644  N.  Peyron,  A.  Coulon
F (b) an
W
F
a
•
•
•
•
•igure 2. Axial T1 sequences before (a) and after fat saturation 
hat is your diagnosis?
rom  the  observations,  what  would  your  diagnosis  be  from
mong  the  following:
mucinous  cystadenoma;
serous  cystadenocarcinoma;
granulosa  cell  tumour;
D
S
Cd T1 GE subtraction 50 seconds after gadolinium injection (c).
struma ovarii  with  pseudo-Meigs’  syndrome  and  raised
CA125;
mucinous  cystadenocarcinoma.iagnosis
truma  ovarii  with  pseudo-Meigs’  syndrome  and  raised
A125.
645
Figure 3. Axial T2 sequence showing a monolocular left ovarian
lesion with loculi of variable T2 signal: T2 hypersignal (black arrow)
and clear (white arrow) or less marked (arrowhead) T2 hyposignal;
pelvic ascites (star).Struma  ovarii,  pseudo-Meigs’  syndrome  and  raised  CA125  
Comments
The  pelvic  ultrasound  examination  was  only  performed  using
the  suprapubic  method.  Transvaginal  ultrasound  was  not
undertaken  given  the  age  of  the  patient  and  her  refusal.
The  pelvic  MRI  showed  a  left  ovarian  lesion,  the  largest
diameter  of  which  was  7  cm.  It  was  of  mixed  type,  with
a  polylobular  shape.  It  had  a  ﬂeshy  tissue  portion  and
septa  with  an  intermediate  signal  in  T2  and  T1  (before  and
after  fat  saturation)  which  became  intensely  enhanced  after
injection.  The  cystic  portion  was  formed  from  many  loculi
with  varying  signals,  separated  by  the  septa.  Some  loculi
appeared  as  a  hyposignal  in  T1  and  T2,  others  had  a  haemor-
rhagic  appearance  with  a  T2  hyposignal  and  a  T1  hypersignal
before  and  after  fat  saturation.  Finally,  there  were  pure  cys-
tic  loculi  in  T2  hypersignal  and  T1  hyposignal  (Figs.  3  and  4).
There  was  no  fatty  component  or  calciﬁcation.
There  was  moderately  abundant  ascites  (Fig.  3).  There
was  no  evidence  of  lymphadenopathy  or  of  any  peritoneal
carcinomatosis  nodules.  The  multilocular  character  with
loculi  with  a  variable  signal  was  very  suggestive  of  struma
ovarii.  However,  the  presence  of  ascites  and  the  raised
CA125  could  not  formally  eliminate  a  malignant  epithelial
Figure 4. Axial T1 sequences before (a) and after fat saturation (b) 
a: presence of loculi in clear T1 hyposignal (red arrow) and others in 
hypersignal T1 (white arrow) before (a) and after fat saturation (b) in
intense enhancement of the ﬂeshy part and walls of the loculi.and T1 GE subtraction 50 seconds after gadolinium injection (c).
less clear T1 hyposignal (arrowhead); a, b: presence of loculi in
dicating haemorrhagic changes. Absence of fatty component; c:
646  N.  Peyron,  A.  Coulon
Table  1  Histopathological  classiﬁcation  of  ovarian  tumours.
Epithelial  tumours  Serous  tumours:
60%  of  ovarian  tumours  Serous  cystadenomas  (60%  of  serous  tumours)
85%  of  malignant  tumours  Border-line  tumours  (15%  of  serous  tumours)
Serous  cystadenocarcinoma  (25%  of  serous  tumours  and  25—35%  of  malignant
tumours)
Mucinous  tumours:
Mucinous  cystadenomas  (80%  of  mucinous  tumours)
Border-line  tumours  (10—15%  of  mucinous  tumours)
Mucinous  cystadenocarcinomas  (5—10%  of  mucinous  tumours  and  5%  of  malignant
tumours)
Endometrioid  tumours:
(15—20%  of  malignant  tumours,  malignant  in  97%  of  cases)
Others:
Clear  cell  (5%  of  malignant  tumours)  or  transitional  cell  adenocarcinomas
(Brenner  tumours)  (4%  of  ovarian  tumours,  benign  in  98%  of  cases),
undifferentiated  carcinomas  etc.
Sex  cord/stromal  tumours Stromal  tumours:
8%  of  ovarian  tumours Granulosa  cell  tumours  (<  10%  of  sex  cord/stromal  tumours)
Fibrothecal  stromal  tumours  (90%  of  sex  cord/stromal  tumours):  ﬁbromas,
ﬁbrothecomas  etc.
Sex  cord  tumours:
(0.5%  of  ovarian  tumours):  Sertoli  and  Leydig  cell  tumours
Germ  cell  tumours Dysgerminomas  or  seminomas  (rare)
20—30%  of  ovarian  tumours  Teratomas:
Immature  (<  1%  of  teratomas)
Mature  solid  or  above  all  cystic  (dermoid  cyst  -  95%  of  germ  cell  tumours)
Specialised  monodermal:  struma  ovarii  (3%  of  teratomas),  carcinoid,
neurectodermal
Metastatic  tumours  Endometrium,  breast,  digestive  tube  (Krükenberg  tumours)
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T5—10%  of  ovarian  tumours
esion.  Ovariectomy  was  thus  scheduled,  by  laparoscopy,
ith  conversion  to  laparotomy  if  a  malignant  epithelial
esion  was  found  on  extemporaneous  examination.  The
xtemporaneous  histopathological  examination  conﬁrmed
he  presence  of  thyroid  tissue.  The  deﬁnitive  histological
xamination  concluded  that  it  was  a  struma  ovarii  with
o  signs  of  malignancy,  and  therefore  a  struma  ovarii  with
seudo-Meigs’  syndrome  and  raised  CA125.
iscussion
t  is  not  always  easy  to  characterise  ovarian  tumours
y  imaging.  The  classically  accepted  criteria  of  malig-
ancy  can  be  found  wanting.  We  usually  consider  organic
varian  lesions  to  be  malignant  if  they  have  irregular
hick  walls  and  septa  (>  4  mm),  an  irregular  ﬂeshy  com-
onent,  necrotic-haemorrhagic  changes,  calciﬁcations  and
econdary  locations  (peritoneal  implants,  ascites,  adenome-
alies)  [1].
Struma  ovarii  (or  thyroid  goitre)  is  a  monodermal  mature
eratoma  composed  mainly  or  exclusively  of  thyroid  tissue
Table  1).  It  is  a  rare  lesion  representing  0.3  to  1%  of  ovarian
umours  and  3%  of  teratomas  [2].This  lesion  is  usually  benign  (95  to  99.9%  of  cases)  and
nilateral.  Malignant  forms  are  rarely  metastatic  (0.1  to
.3%)  [3].  No  recurrence  has  been  described  for  benign  forms
4].
l
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wPatients  are  usually  premenopausal  (85%)  with  a  median
f  42  years  of  age.  Clinical  symptoms  are  often  frustrat-
ng,  diagnosis  being  fortuitous  or  because  of  pelvic  pain,  a
elvic  mass  or  menstrual  disorders  [5].  Sometimes  there  are
ymptoms  of  hyperthyroidism  (5  to  8%  of  cases)  with  changes
n  thyroid  function  tests  [6].  This  diagnosis  should  also  be
onsidered  if  thyroid  scintigraphy  is  negative  with  normal
r  raised  thyroglobulin  levels,  or  if  hyperthyroid  symptoms
ersist  after  total  thyroidectomy.
Given  the  rarity  of  malignant  forms  and  the  hormonal  sta-
us  of  the  patients,  it  is  important  to  consider  the  possibility
f  struma  ovarii  preoperatively  in  order  to  plan  a  conserva-
ive  procedure  (laparoscopic  homolateral  ovariectomy)  [7].
As  with  any  assessment  of  an  ovarian  tumour,  pelvic  ultra-
ound,  preferably  transvaginal,  can  characterise  the  lesion
airly  precisely.  Struma  ovarii  usually  presents  in  the  form
f  a  mixed  cystic  and  tissue  lesion,  with  septa  and  vegeta-
ion  [8—10]. Moderate  hypervascularity  is  present  in  Doppler
ltrasound  [9],  related  to  the  richer  vascularisation  of  thy-
oid  tissue  compared  with  that  of  the  tissue  components
f  other  teratomas.  MRI  signs  are  more  speciﬁc.  The  lesion
ppears  as  multilocular,  mixed  and  heterogeneous  with  poly-
obular  borders.  The  loculi  correspond  to  thyroid  follicles.
heir  signal  varies  depending  whether  their  content  is  pure
iquid  (T2  hypersignal  and  T1  hyposignal)  or  colloid  (T1  and
2  hyposignal)  (associating  thyroglobulin  and  thyroid  hor-
ones)  [11—14]. Haemorrhagic  changes  can  also  be  seen
ith  loculi  in  T1  hypersignal  before,  and  T2  hyposignal
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[Struma  ovarii,  pseudo-Meigs’  syndrome  and  raised  CA125  
after,  fat  saturation.  The  septa  and  tissue  parts  take  up
the  contrast  after  injection  of  gadolinium  because  of  the
rich  vascularity  of  the  thyroid  tissue  [11—13]. There  are
no  speciﬁc  malignancy  criteria  for  a  struma  ovarii  in  imag-
ing,  apart  from  signs  of  metastatic  dissemination  (pelvic
or  lumbar  lymph  nodes,  peritoneal  carcinomatosis,  distant
metastases)  [2].  When  faced  with  a  multilocular  lesion,
differential  diagnoses  include  serous  cystadenocarcinoma
with  necrotic-haemorrhagic  changes,  mucinous  epithelial
tumours  and  ovarian  metastases  of  thyroid  cancer.  More
rarely  the  diagnosis  is  made  in  the  context  of  pseudo-Meigs’
syndrome  with  ascites  (and  less  often  hydrothorax),  when
the  criteria  for  malignancy  are  then  found  wanting.  The
lesions  are  usually  large,  with  considerable  haemorrhagic
and  oedematous  changes  [15].
In exceptional  cases,  as  here,  struma  ovarii  can  be  found
associated  with  pseudo-Meigs’  syndrome  and  raised  CA125
[16—22].  This  is  in  fact  the  ninth  case  in  French  and  English
literature.
Struma  ovarii  should  therefore  be  considered  as  a  pos-
sible  aetiology  when  a  pelvic  tumour,  Meigs’  syndrome  and
raised  tumour  markers  are  associated.  Ascites  disappears
and  the  tumour  markers  return  to  normal  after  surgical
excision.  The  other  differential  diagnoses  in  particular  to
consider,  given  a  pseudo-malignant  ovarian  lesion,  are  atyp-
ical  mature  teratomas  and  cystadenoﬁbromas.  Struma  ovarii
is  a  rare  ovarian  tumour  which  can  mimic  a  malignant
epithelial  lesion,  even  though  it  is  a  monodermal  teratoma
composed  of  thyroid  tissue  which  is  benign  in  most  cases.  It
is  essential  to  consider  the  possibility  given  certain  typical
MRI  characteristics,  in  order  to  plan  conservative  surgery
with  extemporaneous  examination,  in  patients  who  are
usually  premenopausal.  Struma  ovarii  should  be  included
henceforth  among  the  differential  diagnoses  of  malignant
epithelial  ovarian  tumour  when  confronted  with  an  ovarian
tumour  associated  with  pseudo-Meigs’  syndrome  and  raised
CA125.
Disclosure of interest
The  authors  declare  that  they  have  no  conﬂicts  of  interest
concerning  this  article.
References
[1] Bouic-Pagès E, Perrochia H, Mérigeaud S, Giacalone PY, Taourel
P. Corrélations anatomopathologiques : IRM des tumeurs ovari-
ennes primitives. J Radiol 2009;90:787—802.
[2] Kunstmann L, Fénichel P. Goitre ovari une forme particulière
de tératome de l’ovaire. Gynecol Obstet Fertil 2007;35:49—54.
[3] Dardik RB, Dardik M, Westra W, Montz FJ. Malignant struma
ovarii: two case reports and a review of literature. Gynecol
Oncol 1999;73:447—51 [Matsuda K, Maheama T, Kanazawa K.
Malignant struma ovarii with thyrotoxicosis. Gynecol Oncol
2001; 82: 575—7].
[647
[4] Bournaud C, Neel M, Decaussin M, Carreau A, Bertholon-
Grégoire M, Orgiazzi J. Les goitres ovariens. In: Guéritée N,
Leclère J, editors. Mises au point cliniques d’endocriologie,
nutrition et métabolisme. Franconville: Éditions de Médecine
pratique; 2004. p. 193—206.
[5] DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii:
a case report and analysis of cases reported in the litera-
ture with focus on survival and 131I therapy. Gynecol Oncol
2003;89:543—8.
[6] Dunzendorfer T, deLas Morenas A, Kalir T, Levin RM. Struma
ovarii and hyperthyroidism. Thyroid 1999;9:499—502.
[7] Salomon LJ, Lefevre M, Cortez A, Antoine JM, Uzan S. Goitre
ovarien : une tumeur rare et particulière, à propos d’un cas
et revue des modalités de prise en charge. J Gynécol Obstet
2003:32.
[8] Van de Moortele K, Vanbeckevoort D, Hendrickx S. Struma
ovarii: US and CT ﬁndings. JBR-BTR 2003;86(4):209—10.
[9] Zalel Y, Seidman DS, Oren M, Achiron R, Gotlieb W, Mashiah S,
et al. Sonographic and clinical characteristics of struma ovarii.
Am J Ultrasound Med 2000;19:857—61.
10] Savelli L, Testa AC, Timmerman D, Paladini D, Ljungberg
O, Valentin L. Imaging of gynecological disease: clinical and
ultrasound characteristics of struma ovarii. Ultrasound Obstet
Gynecol 2008;32:210—9.
11] Joja I, Asakawa T, Mitsumori A, Nakagawa T, Hiraki Y, Kudo T,
et al. Struma ovarii: appearance at MR imaging. Abdom Imaging
1998;23(6):652—6.
12] Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas:
tumor types and imaging characteristics. Radiographics
2001;21:475—90.
13] Kim JC, Kim SS, Park JY. MR ﬁndings of struma ovarii. Clin
Imaging 2000;24(1):28—33.
14] Damarey B, Farine M, Vinatier D, Collinet P, Lucot J, Kerdraon
O, et al. Mature and immature ovarian teratomas: US, CT and
MR imaging features. J Radiol 2010;91(1 Pt 1):27—36.
15] Zannoni GF, Gallotta V, Legge F, Tarquini E, Scambia G, Fer-
randina G. Pseudo Meigs’ syndrome associated with malignant
struma ovarii: a case report. Gynecol Oncol 2004;94:226—8.
16] Bethune M, Quinn M, Rome R. Struma ovarii presenting as acute
pseudo-Meigs syndrome with an elevated CA 125 level. Aust N
Z J Obstet Gynaecol 1996;36(3):372—3.
17] Long CY, Chen YH, Chen SC, Lee JN, Su JH, Hsu SC.
Pseudo-Meigs syndrome and elevated levels of tumor mark-
ers associated with benign ovarian tumors—two case reports.
Kaohsiung J Med Sci 2001;17(11):582—5.
18] Huh JJ, Montz FJ, Bristow RE. Struma ovarii associated with
pseudo-Meigs’ syndrome and elevated serum CA 125. Gynecol
Oncol 2002;86(2):231—4.
19] Bokhari A, Rosenfeld GS, Cracchiolo B, Heller DS. Cystic struma
ovarii presenting with ascites and an elevated CA-125 level. A
case report. J Reprod Med 2003;48(1):52—6.
20] Loizzi V, Cormio G, Resta L, Fattizzi N, Vicino M, Selvaggi L.
Pseudo-Meigs syndrome and elevated CA125 associated with
struma ovarii. Gynecol Oncol 2005;97(1):282—4.
21] Obeidat BR, Amarin ZO. Struma ovarii with pseudo-Meigs’
syndrome and elevated CA125 levels. J Obstet Gynaecol
2007;27(1):97—8.22] Mitrou S, Manek S, Kehoe S. Cystic struma ovarii present-
ing as pseudo-Meigs’ syndrome with elevated CA125 levels. A
case report and review of the literature. Int J Gynecol Cancer
2008;18(2):372—5.
